Hyperthyroidism

Hyperthyroidism is a systemic endocrine disorder characterized by excessive thyroid hormone synthesis and secretion, most commonly caused by Graves' disease or toxic nodular goiter.[1][2] Thyrotoxicosis is the broader term encompassing all causes of excess circulating thyroid hormone, including destructive thyroiditis, in which hormone release occurs without increased synthesis.[3] The skeletal consequence of greatest relevance to oral and maxillofacial radiology is secondary osteoporosis: excess thyroid hormone accelerates bone remodeling by enhancing both osteoblast and osteoclast activity, with net bone resorption exceeding formation, resulting in high-turnover bone loss.[2][4] In the jaws, this manifests as generalized osteoporotic changes—trabecular rarefaction, cortical thinning, and reduced radiomorphometric indices—rather than as a discrete focal lesion.[5][6] Management is directed at the underlying thyroid disorder through antithyroid drugs, radioactive iodine, or thyroidectomy, with dental implications centering on recognition of osseous changes and surgical risk assessment.[2]

• Hyperthyroidism specifically denotes disorders involving increased thyroid hormone synthesis by a hyperactive thyroid gland (Graves' disease, toxic multinodular goiter, toxic adenoma).[3]
• Thyrotoxicosis is the general term for excess circulating thyroid hormone from any cause, including thyroiditis and exogenous hormone ingestion.[1][3]
• Graves' disease (eponymous for Robert Graves) is the autoimmune form driven by thyrotropin receptor antibodies (TRAb); synonyms include Basedow's disease (used in continental Europe) and diffuse toxic goiter.[7][8]
• Toxic multinodular goiter (Plummer's disease) and toxic adenoma are the principal non-autoimmune causes of hyperthyroidism.[2]
• The term "thyroid osteodystrophy" occasionally appears in older literature to describe the skeletal effects of thyroid hormone excess but is not part of current classification systems.

Graves' disease is the most common cause of hyperthyroidism in iodine-replete populations, with an annual incidence of 20–50 per 100,000 persons.[7][8] Peak onset occurs between ages 30 and 50, though any age may be affected.[7] The lifetime risk is approximately 3% for women and 0.5% for men, yielding a female-to-male ratio of roughly 5–10:1.[8][9] Toxic nodular disease is the second most common cause and predominates in iodine-deficient regions.[2] Genetic factors account for an estimated 79% of the risk for Graves' disease, with HLA-DR3 carrying the highest susceptibility.[8] Skeletal effects are most clinically significant in postmenopausal women and older men, in whom overt and even subclinical hyperthyroidism is associated with substantially increased fracture risk.[2][10]

Systemic presentation

Common symptoms include palpitations, tremulousness, heat intolerance, weight loss, anxiety, insomnia, and diarrhea.[2] Physical findings include tachycardia, fine tremor, warm moist skin, and diffuse thyroid enlargement (goiter), often with an audible bruit in Graves' disease.[2][11] Extrathyroidal manifestations of Graves' disease include ophthalmopathy (proptosis, lid retraction), pretibial myxedema, and acropachy.[11] Older patients may present with apathetic hyperthyroidism with minimal symptoms.[2] Atrial fibrillation occurs in 10–25% of thyrotoxic patients.[2]

Oral and maxillofacial findings

• Accelerated dental development and premature eruption are recognized in children with hyperthyroidism, reflecting the stimulatory effect of thyroid hormones on hard tissue maturation. Severe fetal or neonatal thyroid hormone excess may contribute to craniosynostosis.[12][13][14]
• Osteoporotic jaw changes may be detectable on panoramic radiographs as reduced mandibular cortical dimensions and altered trabecular patterns (discussed in the radiographic section).[5][6]
• Salivary changes: Hyperthyroidism alters salivary composition, with increased flow rate but decreased total protein and calcium concentrations. Autoimmune thyroid disease has been associated with subjective oral dryness and increased caries experience, though the relationship is more consistently demonstrated in hypothyroidism.[15][16][17]
• Burning mouth syndrome has been linked to thyroid hormone abnormalities, predominantly hypothyroidism rather than hyperthyroidism.[18]
• Periodontal disease: A bidirectional association between periodontitis and thyroid disease has been proposed, mediated by shared inflammatory pathways, though hyperthyroidism is not classified among the systemic diseases that independently cause periodontal tissue loss.[19][20]

Hyperthyroidism does not produce a discrete focal jaw lesion. Its radiographic manifestations are diffuse, reflecting the systemic effect of high-turnover osteoporosis on the maxillofacial skeleton. Changes are typically subtle and may be the first imaging clue to undiagnosed metabolic bone disease.

Location and distribution

• Osteoporotic changes affect both jaws but are more readily assessed in the mandible, where cortical and trabecular landmarks are well visualized on panoramic radiography.[5][6]
• Trabecular-rich regions—the mandibular ramus, angle, and retromolar area—are preferentially affected, while the anterior mandibular cortex may be relatively preserved in early disease.[6]

Internal architecture

• The characteristic finding is generalized trabecular rarefaction: the normal fine, well-connected trabecular pattern becomes coarsened, sparse, and less organized.[6][21]
• Fractal analysis of panoramic radiographs demonstrates significantly lower fractal dimension values in hyperthyroid patients compared with euthyroid controls, particularly in the ramus and angle regions, indicating reduced trabecular complexity.[6]
• In advanced disease, a diffusely radiolucent or "washed-out" appearance of the medullary bone may be apparent, though this is a nonspecific finding shared with other metabolic bone diseases.

Periphery and cortical involvement

• Mandibular inferior cortical thinning is a common finding. Radiomorphometric studies show significantly reduced panoramic mandibular index (PMI) and antegonial index (AI) values in hyperthyroid patients compared with matched controls.[5]
• The mandibular cortical index (MCI), which grades cortical erosion morphology, may show mild-to-moderate erosion (C2 pattern), though this finding has not consistently reached statistical significance in hyperthyroid cohorts.[5]
• Cortical bone-rich sites such as the inferior mandibular border may be affected later than trabecular regions.[6][10]

Effects on teeth and adjacent structures

• Loss of lamina dura is occasionally described in the context of metabolic bone disease from thyroid dysfunction, though it is more characteristically associated with hyperparathyroidism. When present in hyperthyroidism, it reflects generalized demineralization rather than a specific endocrine effect on the periodontal ligament.[22][23]
• Widening of the periodontal ligament space is not a recognized feature of hyperthyroidism (unlike hyperparathyroidism).[24]
• Accelerated dental development may be apparent on panoramic radiographs of children, with advanced root formation and eruption relative to chronological age.[12][13]
• Premature tooth eruption in pediatric patients can be assessed radiographically by comparing dental maturation scores with age-matched norms.[12]

Growth pattern and extent

• Changes are generalized and bilateral, reflecting the systemic nature of the metabolic disturbance.
• Severity correlates with duration and degree of thyrotoxicosis; subclinical hyperthyroidism produces milder changes, predominantly in postmenopausal women.[2][10]
• Bone changes may be partially reversible with restoration of the euthyroid state, though recovery is incomplete in patients with prolonged disease duration.[25][26]

Recognized variants

• Pediatric hyperthyroidism (most commonly Graves' disease) may show advanced bone age and accelerated dental maturation on panoramic radiographs, in addition to the osteoporotic changes seen in adults.[12][14]
• Exogenous thyrotoxicosis from excessive levothyroxine replacement or TSH-suppressive therapy produces identical osseous changes; this iatrogenic cause should be considered when panoramic findings suggest metabolic bone disease in a patient with a history of thyroid surgery or thyroid cancer.[27]

Thyroid scintigraphy

Radioactive iodine (¹²³I) or technetium-99m pertechnetate scintigraphy is the reference imaging modality for determining the etiology of thyrotoxicosis. In Graves' disease, uptake is diffusely increased throughout the gland, whereas toxic adenoma shows focal uptake with suppressed surrounding tissue, and thyroiditis shows low or absent uptake.[2][28]

Thyroid ultrasound

Color-flow Doppler ultrasonography demonstrates diffusely increased thyroid vascularity ("thyroid inferno") in Graves' disease, distinguishing it from destructive thyroiditis (decreased flow).[2][8] Sensitivity for Graves' disease diagnosis is approximately 92%, though specificity is lower (~70%).[2] Ultrasound is the preferred imaging modality when scintigraphy is contraindicated, such as during pregnancy.[28]

Skeletal densitometry

Dual-energy X-ray absorptiometry (DXA) is the standard for quantifying bone mineral density loss. Cortical bone-rich sites (distal radius, femoral neck) are preferentially affected in hyperthyroidism.[10][27] DXA findings guide decisions regarding bisphosphonate therapy and fracture risk assessment.[29]

The radiographic changes of hyperthyroidism in the jaws are nonspecific manifestations of metabolic bone disease. The principal diagnostic challenge is distinguishing hyperthyroid osteoporosis from other systemic conditions that produce generalized jaw demineralization, cortical thinning, and trabecular rarefaction. Clinical history, serum thyroid function tests, and additional laboratory studies are essential for differentiation.

The highest-risk diagnostic pitfall is failing to distinguish hyperthyroidism from primary hyperparathyroidism, as both produce generalized jaw demineralization and may coexist. Serum calcium, PTH, TSH, and free T4 levels should be obtained when panoramic radiographs reveal unexplained generalized osteoporotic changes, particularly in younger patients or those without conventional osteoporosis risk factors.[5][11]

Hyperthyroidism does not produce a pathognomonic jaw lesion requiring biopsy. The histopathologic changes are those of high-turnover osteoporosis affecting the maxillofacial skeleton.

Bone remodeling changes

• The remodeling cycle is accelerated to approximately 3–4 months (normal: ~6–7 months), with an increased number of osteoclast resorption sites and a net deficit in bone formation per cycle.[4]
• Iliac crest biopsy studies in hyperthyroid patients demonstrate approximately 9.6% loss of mineralized bone per remodeling cycle, compared with net bone gain in hypothyroid states.[4]
• Histologically, increased osteoclastic activity is evident with numerous Howship's lacunae, thin and disconnected trabeculae, and widened marrow spaces filled with fibrovascular tissue.[26][38]

Osteocytic osteolysis

Animal models demonstrate that hyperthyroidism induces osteocytic osteolysis, with increased tartrate-resistant acid phosphatase (TRAP) activity in osteocytes and reduced perilacunar mineralization.[26] These changes may persist even after restoration of the euthyroid state, suggesting a mechanism for ongoing bone quality impairment beyond what is captured by densitometry.[26]

Radiologic-pathologic correlation

The trabecular rarefaction and cortical thinning observed on panoramic radiographs correspond to the histologic findings of increased resorption surfaces, reduced trabecular number and connectivity, and endosteal cortical erosion. The absence of focal lesions, giant cells in a reparative stroma, or ground-glass fibro-osseous replacement distinguishes hyperthyroid bone from hyperparathyroidism and fibrous dysplasia, respectively.

Endocrine management

Treatment of the underlying thyroid disorder is the primary intervention. The 2016 American Thyroid Association (ATA) guidelines recommend individualized treatment selection among three modalities:[2][28]

• Antithyroid drugs (methimazole preferred; propylthiouracil in first trimester of pregnancy): first-line for Graves' disease, with a 12–18 month course achieving long-term remission in 30–50%. Favorable remission predictors include mild disease, small goiter, and low TRAb titers.[2][28]
• Radioactive iodine (¹³¹I): achieves resolution in ~93% but causes permanent hypothyroidism in nearly all Graves' disease patients and carries a small risk of worsening thyroid eye disease.[2]
• Thyroidectomy: near-complete efficacy (99% for total thyroidectomy) but carries risks of recurrent laryngeal nerve injury and hypoparathyroidism (4–6%).[2]

Dental and surgical implications

• Preoperative assessment: Patients with known or suspected hyperthyroidism undergoing oral and maxillofacial surgery should have thyroid function normalized before elective procedures to reduce risks of thyroid storm, cardiac arrhythmia, and impaired wound healing.[2]
• Osseous healing considerations: Reduced bone mineral density may affect implant osseointegration and fracture healing. Radiomorphometric assessment on panoramic radiographs (PMI, AI) can help stratify osteoporotic risk before surgical planning.[5]
• Medication-related considerations: Patients rendered hypothyroid after definitive treatment require lifelong levothyroxine; excessive replacement doses (iatrogenic subclinical hyperthyroidism) perpetuate bone loss and should be monitored.[27]

Skeletal prognosis

• Bone mineral density partially recovers after restoration of the euthyroid state, particularly in younger patients and those with shorter disease duration.[25][29]
• Persistent bone loss may occur despite biochemical euthyroidism, potentially mediated by ongoing TRAb effects on bone.[29]
• Postmenopausal women and older men with Graves' disease may benefit from adjunctive bisphosphonate therapy to enhance BMD recovery.[29]

Pediatric hyperthyroidism

Graves' disease in children and adolescents may present with growth acceleration, advanced bone age, and accelerated dental development.[12][14] Craniosynostosis is a rare but serious complication of severe fetal or neonatal thyrotoxicosis.[13][14] Panoramic radiographs may reveal dental maturation advanced relative to chronological age. Bone health recovery after treatment is more favorable with shorter disease duration, emphasizing the importance of early diagnosis.[25]

Pregnancy

Gestational transient thyrotoxicosis, driven by hCG stimulation of the TSH receptor, is physiologic and self